Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership ...
The Manila Times21h
Transactions In Connection with Share Buy-back Program
The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour ...